{
    "root": "9e588c43-b9b5-478e-99f7-e197add3cd26",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levothyroxine Sodium",
    "value": "20250401",
    "ingredients": [
        {
            "name": "D&C RED NO. 27",
            "code": "2LRS185U6K"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "D&C RED NO. 30",
            "code": "2S42T2808B"
        },
        {
            "name": "SODIUM STARCH GLYCOLATE TYPE A POTATO",
            "code": "5856J3G2A2"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "LEVOTHYROXINE SODIUM",
            "code": "9J765S329G"
        }
    ],
    "indications": "Hypothyroidism\n                  \n                  Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.\n                  \n                     Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression\n                  \n                  Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.\n                  \n                     Limitations of Use:\n                      • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)].  \n                  • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.",
    "contraindications": "• Administer once daily, preferably on an empty stomach, one-half to one hour before breakfast. (2.1) • Administer at least 4 hours before or after drugs that are known to interfere with absorption. (2.1) • Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. (2.1) • Starting dose depends on a variety of factors, including age, body weight, cardiovascular status and concomitant medications. Peak therapeutic effect may not be attained for 4-6 weeks. (2.2) • See full prescribing information for dosing in specific patient populations. (2.3) • Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. (2.4)",
    "warningsAndPrecautions": "Levothyroxine Sodium Tablets, USP are supplied as follows:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              Strength (mcg)\n                           \n                           \n                              Color/Shape\n                           \n                           \n                              Tablet Markings\n                           \n                           \n                              NDC# for bottles of 90\n                           \n                        \n                     \n                     \n                        \n                           \n                              100\n                           \n                           \n                              Yellow/ Caplet\n                           \n                           \n                              \"100\" and \"GG/335\"\n                           \n                           \n                              82804-222-90",
    "adverseReactions": "Levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency     [see Warnings and Precautions (5.3)] ."
}